Skip to content

Fighting to Preserve the Benefits of the 340B Program

  • About Us
  • Contact Us
Top Bar Menu
Facebook page opens in new windowTwitter page opens in new windowLinkedin page opens in new windowMail page opens in new window
RWC-340B
Ryan White Clinics for 340B Access
RWC-340B
  • Members
    • RWC-340B Members
    • Become a Member
  • Benefactors
    • Meet Our Benefactors
    • Benefactor Application
  • Expert Advice
    • Outline of Technical Assistance
    • Peer-to-Peer Mentoring
  • Advocacy
    • TAKE ACTION
    • Congressional Advocacy
    • Regulatory Advocacy
    • State Advocacy
    • Litigation
  • Issues
    • Contract Pharmacy
    • Discriminatory Reimbursement Toolkit
    • Carve-out Toolkit
    • PrEP Toolkit
    • COVID-19 Toolkit
    • RWC-340B Key Research
  • Events
    • Conferences
    • Webinars
  • News
Search:
  • Members
    • RWC-340B Members
    • Become a Member
  • Benefactors
    • Meet Our Benefactors
    • Benefactor Application
  • Expert Advice
    • Outline of Technical Assistance
    • Peer-to-Peer Mentoring
  • Advocacy
    • TAKE ACTION
    • Congressional Advocacy
    • Regulatory Advocacy
    • State Advocacy
    • Litigation
  • Issues
    • Contract Pharmacy
    • Discriminatory Reimbursement Toolkit
    • Carve-out Toolkit
    • PrEP Toolkit
    • COVID-19 Toolkit
    • RWC-340B Key Research
  • Events
    • Conferences
    • Webinars
  • News

Gilead

RWC-340B Sends Letters to Gilead, HHS Secretary, and OPA Director.

Congress, Drug Pricing, HHS, HRSA, Regulations, RWC-340BBy Amber TynanApril 15, 2022

A growing number of pharmaceutical manufacturers have recently posed restrictions affecting Ryan White Clinics and other Safety Net Providers. RWC-340B has taken action to address these challenges head-on.   On…

Spanberger

Spanberger to HHS: Hold Drug Companies Accountable for Breaking the Law, Crack Down on Illegal Price Hikes

Drug Pricing, HHS, NewsBy Amber TynanJanuary 26, 2022

In response to a rash of reckless decisions by pharmaceutical companies, U.S. Representative Abigail Spanberger is leading a bipartisan effort to protect the 340B Drug Pricing Program and prevent additional…

volodymyr hryshchenko m1Hq4ibP9rc unsplash

New AbbVie and Lilly Contract Pharmacy Policies

Drug Pricing, HHS, HRSA, NewsBy Andrea JeriaJanuary 6, 2022

AbbVie is the 11th Manufacturer to Restrict Access to 340B Prices at Contract Pharmacies By letter dated December 29, 2021, AbbVie announced that, effective February 1, 2022, it will implement…

glsun guilin WNX6uk 1LV4 unsplash

UCB Latest Manufacturer to Announce Restrictive Contract Pharmacy Policy; HRSA Issues Statement Regarding Manufacturer Lawsuits

Drug Pricing, HHS, HRSA, NewsBy Andrea JeriaNovember 23, 2021

By letter dated November 22, 2021, drug manufacturer UCB, Inc. notified covered entities that it is “altering its 340B policy” and will no longer honor contract pharmacy arrangements, effective December…

courthouse g329b35186 1280

Update on 340B Contract Pharmacy Litigation — Decisions Issued in Four Manufacturer Lawsuits

Drug Pricing, HHS, HRSA, News, RulingsBy Andrea JeriaNovember 8, 2021

On Friday, November 5, two federal courts issued decisions in four of the lawsuits that drug manufacturers filed against HHS challenging HHS’ May 17 cease-and-desist letters (“May 17 Letters”) notifying…

RWC 340B Logo hi res

RWC-340B Applauds Court’s “Fairest and Most Reasonable” Interpretation of the 340B Drug Pricing Program: Manufacturer Actions Shall Not Undermine the Safety Net

Drug Pricing, HHS, HRSA, News, RWC-340BBy Andrea JeriaNovember 2, 2021

PRESS STATEMENT: FOR IMMEDIATE RELEASE         Contact: Peggy.Tighe@PowersLaw.com RWC-340B Applauds Court’s “Fairest and Most Reasonable” Interpretation of the 340B Drug Pricing Program:  Manufacturer Actions Shall Not Undermine the Safety Net…

index

Indiana Federal Court Issues Decision in Eli Lilly’s Contract Pharmacy Lawsuit

Drug Pricing, HHS, HRSA, News, Rulings, RWC-340BBy Andrea JeriaNovember 1, 2021

On Friday, the U.S. District Court for the Southern District of Indiana (the Court) issued a decision supporting HRSA’s statutory interpretation, as reflected in HRSA’s May 17 determination, that Eli…

istockphoto 1285497344 612x612 1

Boehringer Ingelheim Is Latest Manufacturer to File a Lawsuit Against HHS On Contract Pharmacy Program

Drug Pricing, HHS, HRSA, RWC-340BBy Andrea JeriaOctober 26, 2021

On October 25, 2021, drug manufacturer Boehringer Ingelheim Pharmaceuticals, Inc. filed a lawsuit in the U.S. District Court for the District of Columbia against HHS, alleging that HHS’s policy on…

tingey injury law firm nSpj Z12lX0 unsplash

Kalderos Sues HHS Over Contract Pharmacy Policy

HHS, HRSA, NewsBy Andrea JeriaOctober 11, 2021

On October 7, technology company Kalderos Inc. filed a lawsuit in the U.S. District Court for the District of Columbia against HHS alleging that HRSA’s contract pharmacy policy is unlawful. …

waste paper gcbfb8becf 1920

United Therapeutics Seeks Records from HRSA Regarding Covered Entity Compliance with Duplicate Discount and Diversion Prohibitions

Drug Pricing, HHS, HRSA, NewsBy Andrea JeriaOctober 11, 2021

The law firm representing United Therapeutics (UT), Latham & Watkins, has filed a request with HRSA to obtain a wide range of records related to HRSA’s enforcement of the 340B…

→12345…
6
7→
                                                                            © 2021 Ryan White Clinics for 340B Access. RWC-340B is a 501(c)(4) non-profit corporation.
Go to Top
Translate »
Skip to content
Open toolbar Accessibility Tools

Accessibility Tools

  • Increase TextIncrease Text
  • Decrease TextDecrease Text
  • GrayscaleGrayscale
  • High ContrastHigh Contrast
  • Negative ContrastNegative Contrast
  • Light BackgroundLight Background
  • Links UnderlineLinks Underline
  • Readable FontReadable Font
  • Reset Reset